Genomic DNA off-target sites (Off-target sites)

Genomic DNA off-target sites refer to locations in the genome where a gene-editing tool, most commonly the CRISPR-Cas9 system, binds and induces a double-strand break (DSB) despite having only partial complementarity to the single-guide RNA (sgRNA) (Zhang et al., 2015, Molecular Therapy - Nucleic Acids). These sites typically share high sequence similarity with the intended target sequence, allowing the Cas9 nuclease to tolerate a limited number of mismatches, insertions, or deletions (Fu et al., 2013, Nature Biotechnology). The occurrence of off-target effects is a major concern in therapeutic applications because unintended mutations can lead to gene disruptions, chromosomal translocations, or the activation of oncogenes, potentially causing cellular toxicity or cancer (Tsai & Joung, 2016, Nature Reviews Genetics). Various computational and experimental methods, such as GUIDE-seq and CIRCLE-seq, are employed to identify and minimize these risks during drug development (Tsai et al., 2015, Nature Biotechnology). Strategies to mitigate off-target activity include the use of high-fidelity Cas9 variants, optimized sgRNA design, and transient delivery methods to limit the duration of nuclease exposure (Kleinstiver et al., 2016, Nature). These sites are not therapeutic targets themselves but represent a critical safety parameter in the evaluation of genomic medicines.

Other names

CRISPR off-target sitesNon-specific cleavage sitesUnintended genomic modificationssgRNA mismatchesOff-target effects

Unintended binding and cleavage of DNA by CRISPR-Cas complexes due to partial sequence homology, followed by error-prone repair via non-homologous end joining (NHEJ) or homology-directed repair (HDR).